IFN-β treatment of HeLa and HT1080 cells

HeLa (ATTC: CCL-2) and HT1080 (ATCC: CCL-121) cells were cultured as adherent cells at 37 °C with 5% CO₂ in Dulbecco’s modified Eagle’s medium with high glucose and with sodium pyruvate (Life Technologies Europe BV, Nærum, Denmark) with added 10% sterile-filtered fetal bovine serum (FBS) (Sigma-Aldrich, Søborg, Denmark ) and 1% Penicillin-Streptomycin (Pen-Strep) solution (Sigma-Aldrich) at 37 °C and 5% CO2. The human HT1080 and HeLa cell lines used have the AG genotype and the AA genotype, respectively, regarding the SNP rs10774671 [9 (link)]. For interferon treatments, both HeLa and HT1080 cells were grown to ~80% confluence and were treated with 1000 U/mL IFN-β or left untreated for 24–48 h before analysis. Both cell-lines were tested and found mycoplasma free.